A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

10.1038/s41408-021-00544-x

Saved in:
Bibliographic Details
Main Authors: Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli
Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
Format: Letter
Language:English
Published: SPRINGERNATURE 2021
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
MULTIPLE-MYELOMA
LENALIDOMIDE
Online Access:https://scholarbank.nus.edu.sg/handle/10635/207736
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English

Internet

https://scholarbank.nus.edu.sg/handle/10635/207736

Similar Items